GRCE Stock Analysis: Buy, Sell, or Hold?
GRCE - Grace Therapeutics, Inc. Common Stock
$2.17
-0.03 (-1.18%)
▼
5d:
+0.65%
30d:
-6.69%
90d:
-1.18%
BUY
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When GRCE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GRCE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: GRCE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GRCE is currently trading at $2.17, which is considered fair relative to its 30-day fair value range of $2.08 to $2.33.
Technical Outlook: Technically, GRCE is in a downtrend. Immediate support is located at $2.02, while resistance sits at $2.25.
Market Sentiment: GRCE scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.06 (+175.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GRCE is in a downtrend. Immediate support is located at $2.02, while resistance sits at $2.25.
Market Sentiment: GRCE scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.06 (+175.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.08 -
$2.33
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 175.4% below Wall St target ($6.06)
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$2.08 -
$2.33
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.02
Resistance Level
$2.25
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.31
Wall Street Target
$6.06
(+175.4%)
Share & Embed Analysis
Last updated: August 24, 2026 1:30 PM ET
Data refreshes hourly during market hours. Next update: 2:30 PM
Data refreshes hourly during market hours. Next update: 2:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRCE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
|
VERA
Vera Therapeutics Inc |
STRONG BUY
14 analysts |
$77 | 57 HOLD |